Multiple early phase clinical trials with TCBs targeting CD123 (Flotetuzumab and Vibecotamab) or the intracellular tumor antigen Wilms tumor 1 (WT1) presented on HLA-A*02 are currently underway in AML [4–6]. Here, WT1 is linked to acute myeloid leukemia.